-
04.30.2025 | CARB-X releases 2024 Annual Report celebrating a year of progress
CARB-X today published its 2024 Annual Report, highlighting critical action to address antimicrobial resistance (AMR). The report outlines how CARB-X continues to strengthen the antibacterial development ecosystem and accelerate research and development.
-
04.02.2025 | CARB-X funds ArrePath to advance novel antibiotic to treat multidrug-resistant infections
CARB-X will award $3.7 million to ArrePath to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales.
-
02.26.2025 | CARB-X launches 2025 Funding Round targeting global infectious disease threats
CARB-X announces 2025 Funding Round seeking therapeutics for infections caused by Gram-negative pathogens and diagnostics for Salmonella Typhi
-
02.25.2025 | CARB-X funds Immunethep to develop vaccine to prevent E. coli infections
CARB-X will award $2 million to Immunethep to develop a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli.
-
02.11.2025 | CARB-X funds Pearl to assess detection of bacterial pneumonia via urine sample
CARB-X will award biotechnology Pearl Diagnostics US$1.M to develop a low-cost, low turnaround time urine assay for the detection of pneumonia caused by Pseudomonas aeruginosa.
-
02.06.2025 | CARB-X funds AstraDx to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award AstraDx US$3M to demonstrate feasibility ahead of development for a robust, low-cost instrument to detect neonatal sepsis. AstraDx’s technology aims to perform pathogen detection, pathogen identification, and phenotypic antimicrobial susceptibility testing (AST) directly from whole blood and produce results within 4 hours.
-
01.28.2025 | CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia
CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.
-
01.23.2025 | CARB-X funds Immunartes to develop Staphylococcus aureus preventative
CARB-X will award Immunartes US$729k to develop a monoclonal antibody to prevent infections caused by Staphylococcus aureus.
-
01.16.2025 | CARB-X funds Justus Liebig University Giessen to develop antibiotic targeting Gram-negative pathogens
CARB-X will award a seed grant of US$610k to Justus Liebig University Giessen (JLU) to support the definition of a lead optimization path for the development of a direct-acting peptide therapeutic based on a natural-product scaffold targeting Gram-negative pathogens.
-
01.14.2025 | CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics $3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.07.2025 | CARB-X funds Clarametyx Biosciences to develop anti-biofilm vaccine
CARB-X will award Clarametyx Biosciences US$2.6 million to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program.
Toggle navigation